Earnings Releases·Nov 5, 2026, 4:30 PM ET

Gyre Therapeutics — Q3 2026 Earnings Summary

Q3 2026 revenue rose 1% to $32.9 million, though YTD revenue fell 7% to $86.5 million; the company shifted from net income to a GAAP net loss of $2.5 million in Q3 (vs. $1.9 million income in Q3 2025) and $35.3 million YTD (vs. $4.6 million income YTD 2025).
Full-year 2026 revenue guidance of $100.5 million to $111.0 million is affirmed, while cash and equivalents declined 15% to $98.8 million as of September 30, 2026.
The Cullgen acquisition, closed in early May 2026, drove $6.9 million in YTD transaction costs and contributed to a 39% increase in G&A expenses, while the expiration of the Astellas collaboration reduced collaboration revenue by $1.6 million in Q3.
F351 NDA for CHB-induced liver fibrosis is under review with an NMPA decision expected by end of 2026 or Q1 2027, potentially enabling a launch in H1 2027; Phase 2 for CG001419 and Phase 1 for CG009301 are scheduled for 2027.